EXHIBIT 99


            Dragon Pharmaceutical Announces Proposed Private Offering

Vancouver- March 30, 2005. Dragon  Pharmaceutical  Inc. (TSX: DDD; OTC BB: DRUG;
BBSE: DRP) announces that it proposes to offer on a best efforts basis up to $25
million of its securities in a private  placement to accredited  investors.  The
type of securities,  price and completion of the proposed private placement will
depend on, among other things,  market  conditions.  It is anticipated  that the
proceeds from the private placement will be used to serve as the working capital
to ramp up the production of the newly operated  Chemical  division,  to improve
the  Company's  financial  structure  and  to  fund  the  Company's  EPO  market
development in Europe as well as the relocation of the Biotech  facility  within
China. The securities  proposed to be offered in the private  placement will not
be registered  under the Securities Act or any state securities laws, and unless
they are so  registered,  may not be offered or sold in the United States except
pursuant to an exemption from the  registration  requirements  of the Securities
Act and applicable state securities laws.

About Dragon Pharmaceutical Inc.

On January 12, 2005,  Dragon  completed the acquisition of Oriental Wave Holding
Limited.  As a result of the acquisition,  Dragon has transformed  itself into a
diversified   generic    pharmaceutical    diversified   and   growth   oriented
pharmaceutical company with three key business units: Chemical division for bulk
pharmaceutical  chemical  (Clavulanic  Acid and  7-ACA),  Biotech  division  for
recombinant  drugs  (EPO and G-CSF) and Pharma  division  for  prescription  and
over-the-counter drugs.

For further information please contact:
Dragon Pharmaceutical Inc.
Garry Wong, CFA, IMBA
Telephone: +1-(604)-669-8817 or North America Toll Free: 1-877-388-3784
Email: irdragon@dragonpharma.com
Website: www.dragonpharma.com

or

Renmark Financial Communications Inc.
John Boidman : jboidman@renmarkfinancial.com
Sylvain Laberge : slaberge@renmarkfinancial.com
Media - Cynthia Lane : clane@renmarkfinancial.com
Telephone: +1-(514) 939-3989
Website: www.renmarkfinancial.com

This press release shall not constitute an offer to sell or the  solicitation of
an offer to buy any security and shall not constitute an offer,  solicitation or
sale in any  jurisdiction  in which such  offer,  solicitation  or sale would be
unlawful.


                                       1


Cautionary  Statement:  The Company's  statements in this press release that are
not  historical  facts,  and  that  relate  to  future  plans  or  events,   are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform Act of 1995.  These  forward-looking  statements  include the
Company's  intention to raise proceeds through the proposed offering and sale of
its  securities.  There can be no assurance  that the Company will  complete the
proposed  offering on the anticipated  terms or at all. The Company's ability to
complete  the  proposed  offering  will depend on,  among other  things,  market
conditions.  The Company does not  undertake the  obligation to publicly  revise
these forward looking statements to reflect subsequent events or circumstances.

Readers should carefully review the risk factors and other factors described in
its periodic reports with the Securities and Exchange Commission.




                                       2